As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.
Study Type
OBSERVATIONAL
Enrollment
9,600
Quality improvement activities
Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving reperfusion therapy by PCI
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving risk stratification at admission
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients prescribed dual antiplatelet medications at discharge
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients with indications prescribed a beta-blocker at discharge
Time frame: Duration of hospital stay, an expected average of 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Proportion of patients prescribed a statin at discharge
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients with indications prescribed an ACE-I or ARB at discharge
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients that receiving an LDL-C assessment
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients with evaluation for LV systolic function by echocardiography
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of smoking patients that receiving smoking cessation advice/counseling
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving fasting glucose test at least twice
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving HbA1C test
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients with body height and weight measured and documented
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving guidance on individualized dietary
Time frame: Duration of hospital stay, an expected average of 1 week
Proportion of patients receiving guidance on individualized physical activity
Time frame: Duration of hospital stay, an expected average of 1 week